Sermorelin is a lab-made medicine. It copies part of a hormone, a chemical message the brain sends to a small gland beneath it. That gland is called the pituitary. The gland responds by releasing its own growth hormone. Sermorelin itself is a different substance. The review of its earlier uses explains how it works.
Growth hormone is a body signal whose shortage can affect a child’s growth. That growth problem was one of sermorelin’s earlier uses.
For an adult, the question is what benefit is being proposed and whether studies in adults showed it. The evidence briefing follows that question.
What the old approval covered
Sermorelin was sold under the name Geref for different uses. In December 1990, the Food and Drug Administration (FDA) approved its use in a test: could the pituitary gland release growth hormone? In September 1997, FDA approved it as treatment for children who were growing poorly because they lacked growth hormone.
Those were specialist uses, not approval for adult energy, sleep or body shape; this account reflects the record checked on September 28, 2026.
After the maker stopped selling it, Geref’s approvals ended on June 18, 2009. The dates and uses appear in the FDA’s published Geref history.
What that means for an offer now
A September 28, 2026 check of FDA application records found no approved sermorelin product being marketed in the US.
The March 2013 FDA finding addressed why Geref’s sale ended: neither harm nor failure to work was the reason for its withdrawal. That decision does not amount to support for a current preparation or for adult treatment.
An old approval answers an old, specific question.
When someone mentions that history, ask them to finish the thought. Which product are they offering? What problem is it meant to address? What adult evidence supports that purpose?